---
document_datetime: 2023-09-21 20:49:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/aspaveli-epar-all-authorised-presentations_en.pdf
document_name: aspaveli-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8228965
conversion_datetime: 2025-12-26 18:41:42.07953
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form   | Route of administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/21/1595/001 | ASPAVELI          | 1 080 mg   | Solution for infusion | Subcutaneous use          | vial (glass)          | 20 mL (54 mg/mL)          | 1 vial      |
| EU/1/21/1595/002 | ASPAVELI          | 1 080 mg   | Solution for infusion | Subcutaneous use          | vial (glass)          | 20 mL (54 mg/mL)          | 8 vials     |